AMINOSYN 5% SOLUTION

Country: Canada

Language: English

Source: Health Canada

Active ingredient:

L-ISOLEUCINE; L-LEUCINE; L-LYSINE (L-LYSINE ACETATE); METHIONINE; L-PHENYLALANINE; L-THREONINE; TRYPTOPHAN; L-VALINE; L-TYROSINE; L-ALANINE; L-ARGININE; GLYCINE; L-PROLINE; SERINE; HISTIDINE

Available from:

HOSPIRA HEALTHCARE ULC

ATC code:

B05BA01

INN (International Name):

AMINO ACIDS

Dosage:

360MG; 470MG; 360MG; 200MG; 220MG; 260MG; 80MG; 400MG; 44MG; 640MG; 490MG; 640MG; 430MG; 210MG; 150MG

Pharmaceutical form:

SOLUTION

Composition:

L-ISOLEUCINE 360MG; L-LEUCINE 470MG; L-LYSINE (L-LYSINE ACETATE) 360MG; METHIONINE 200MG; L-PHENYLALANINE 220MG; L-THREONINE 260MG; TRYPTOPHAN 80MG; L-VALINE 400MG; L-TYROSINE 44MG; L-ALANINE 640MG; L-ARGININE 490MG; GLYCINE 640MG; L-PROLINE 430MG; SERINE 210MG; HISTIDINE 150MG

Administration route:

INTRAVENOUS

Units in package:

250ML/700ML/800ML/1000ML

Prescription type:

Ethical

Therapeutic area:

CALORIC AGENTS

Product summary:

Active ingredient group (AIG) number: 1550865004; AHFS:

Authorization status:

CANCELLED POST MARKET

Authorization date:

2016-07-29

Summary of Product characteristics

PRESCRIBING INFORMATION
AMINOSYN7 5%
AMINOSYN7 7%
AMINOSYN7 8.5%
AMINOSYN7 10%
AMINOSYN
TM/MD RF INJECTION 5.2%
(amino acids for injection 5%, 7%, 8.5%, 10%, and 5.2% renal formula)
SULFITE-FREE
NUTRITIVE SUPPLEMENT FOR INTRAVENOUS INFUSION
Hospira Healthcare Corporation
Date of Revision: April 11, 2012
1111 Dr. Frederik-Philips, 6
th
floor
St-Laurent,Quebec
H4M 2X6
CONTROL NOS. 150040 AND 150041
_PRESCRIBING INFORMATION; Aminosyn® 5%, 7%, 8.5%, 10% and RF
Injection 5.2% _
_Page 2 of 14 _
NAMES OF DRUGS:
AMINOSYN
7
5%
AMINOSYN
7
7%
AMINOSYN
7
8.5%
AMINOSYN
7
10%
AMINOSYN
TM/MD
RF INJECTION 5.2%
(amino acids for injection 5%, 7%, 8.5%, 10%, and 5.2% renal formula)
Sulfite-Free
THERAPEUTIC OR PHARMACOLOGICAL CLASSIFICATION
Nutritive Supplement for Intravenous Infusion
ACTION
1.
PROTEIN SPARING (PERIPHERAL USE)
:
It has been shown that it may be preferable for short periods of time,
3 to 5 days, to mobilize fat (as
in total starvation) for meeting energy requirements to spare protein.
Under conditions of total fasting, lipid mobilization provides energy
substrate in the form of free fatty
acids and ketone bodies. Lipolysis occurs because insulin levels are
low. If high concentrations of
carbohydrates are administered, insulin levels will rise and inhibit
lipid mobilization. With brief
periods of fasting (less than 24 hours), energy requirements are
usually met by glycogenolysis of the
glycogen stored in the liver. However, after glycogen is depleted,
lipolysis of body fat becomes the
fat source of energy.
Thus, when amino acids (without dextrose) are infused into a
peripheral vein, lipolysis and
ketogenesis occur freely and caloric requirements are met without
proteolysis. This spares protein
and the body's muscle mass, while providing a substrate for essential
protein synthesis.
Amino acid peripheral intravenous infusions result in: (1)
availability of free fatty acids and ketone
bodies as sources of energy, and (2) the concomitant utilization of
administered amino acids for
protein synthesis.
2.
ADJUNCTIVE FOR TO